ArticleIDCases2020
Doxycycline as a potential partner of COVID-19 therapies.
Article in IDCases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 114 citations in OpenAlex.
- COVID-19 prophylaxis with doxycycline and zinc in health care workers: a prospective, randomized, double-blind clinical trial.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Trial
- The Combination of Nirmatrelvir and Ivermectin Exerts Strongly Synergistic Antiviral and Anti-Inflammatory Effects Against Murine Coronavirus Infection of Macrophages.International journal of molecular sciences · 2026Article
- CEBPD-MMP8 Axis Contributes to Cardiomyocyte Injury in Septic Shock.Applied biochemistry and biotechnology · 2026Article
- Repositioning Drugs: A Computational Approach.Current drug research reviews · 2026Review
- A Rapid and Complete Photodegradation of Doxycycline Using rGO@CuO Nanocomposite Under Visible and Direct Sunlight: Mechanistic Insights and Real-Time Applicability.Nanomaterials (Basel, Switzerland) · 2025Article
- Synergistic antibacterial activity of chitosan-polyethylene glycol nanocomposites films containing ZIF-8 and doxycycline.BMC biotechnology · 2025Article
- Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective.Brain, behavior, & immunity - health · 2024Article
- Drug modifications: graphene oxide-chitosan loading enhanced anti-amoebic effects of pentamidine and doxycycline.Parasitology research · 2024Article
- Article
- Drug-Induced Acute Pancreatitis in Hospitalized COVID-19 Patients.Diagnostics (Basel, Switzerland) · 2023Review
- Green ecofriendly electrochemical sensing platform for the sensitive determination of doxycycline.Heliyon · 2023Article
- Antibiotic Utilization during COVID-19: Are We Over-Prescribing?Antibiotics (Basel, Switzerland) · 2023Article
- Viral Infection and Antiviral Treatments in Ocular Pathologies.Microorganisms · 2022Review
- Validation of a noninvasive aMMP-8 point-of-care diagnostic methodology in COVID-19 patients with periodontal disease.Clinical and experimental dental research · 2022Article
- Histopathological and molecular links of COVID-19 with novel clinical manifestations for the management of coronavirus-like complications.Inflammopharmacology · 2022Review
- Pharmacological consideration of COVID-19 infection and vaccines in pregnancy.Journal of the Chinese Medical Association : JCMA · 2022Review
- Type I interferon regulates proteolysis by macrophages to prevent immunopathology following viral infection.PLoS pathogens · 2022Article
- Integrating heterogeneous data to facilitate COVID-19 drug repurposing.Drug discovery today · 2022Review
- The clinical association between Periodontitis and COVID-19.Clinical oral investigations · 2022Article
- Computationally prioritized drugs inhibit SARS-CoV-2 infection and syncytia formation.Briefings in bioinformatics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronavirus disease 2019 (COVID-19) is a major public health challenge, and the current antiviral arsenal for treatment is limited, with questionable efficacy. Major efforts are under way for discovery of new effective agents, but the validation of new potential treatments for COVID-19 may take a long time. Therefore, the repurposing of existing drugs for new indications is needed. In this article, we argue for the potential benefits of using doxycycline with either hydroxycholoroquine or other putative agents for COVID-19 treatment, as doxycycline has antiviral and anti-inflammatory activities by dampening the cytokine storm and to prevent lung damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.